New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For MEDI;PFE;CELG;PRXL;ACOR;NPSP;ALKS;AZN;TEVA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | all recent news | >>
July 2, 2015
18:37 EDTPFEViiV, Desano enter strategic manufacturing agreement for Tivicay
Subscribe for More Information
16:37 EDTCELGStocks end holiday shortened week lower after Greece defaults
Stocks on Wall Street began with a slide on Monday, but not as precipitous a drop as may have been feared, after Greece shut down its banks and announced it will put the concession deal offered by its creditors, and essentially its continued inclusion in the eurozone, up for a popular vote. The major averages regained a bit of their losses in the next two sessions as news regarding the Greek situation continued to dominate the headlines. U.S. markets are closed on Friday in observance of Independence Day, but investors will be returning to big news, for better or worse, following the referendum that is scheduled to occur on July 5. MACRO NEWS: In the U.S., the monthly nonfarm payrolls report showed the addition of 223,000 jobs, versus expectations for 233,000 jobs to have been added last month. The unemployment rate fell to 5.3% from the prior month’s 5.5% rate. Factory orders fell 1.0% in May, which was larger than the expected 0.5% decline. The Conference Board's consumer confidence index rose to 101.4 in June from a revised 94.6 reading for May, beating expectations for a reading of 97.4. Markit's manufacturing purchasing managers' index for June came in at 53.6, narrowly above the 53.4 forecast. ISM's manufacturing index rose to 53.5 in June, topping May's 52.8 reading and the 53.2 consensus forecast. Construction spending rose 0.8% in May, versus the expected growth of 0.5%. Additionally, Puerto Rico's Governor Alejandro Garcia Padilla, in an interview published by the New York Times, warned that the commonwealth's "debt is not payable" and a report warned that the territory's crisis was even worse than previously thought... In Europe, Greek Prime Minister Alexis Tsipras called a surprise referendum on the terms put forth by the country’s creditors in exchange for additional rescue funds and the country shut down its banks until after this Sunday's vote. Standard & Poor's Ratings lowered its sovereign credit ratings on Greece, stating that the probability of the country exiting the eurozone is now about 50%, in its view. Greece officially missed its $1.7B payment to the International Monetary Fund, as expected. Greece's government requested a third bailout from the eurozone, but the request was dismissed by European officials. Eurogroup president Jeroen Dijsselbloem said Wednesday that he saw no need for further talks on Greece at that point as he awaits the result of its referendum... In China, the People’s Bank cut the one-year lending rate by 25 basis points to 4.85% and lowered the amount of reserves certain banks are required to hold by 50 basis points, but the same day the Shanghai Composite entered bear market territory, meaning the index was down more than 20% from its peak in mid-June. Chinese manufacturing PMIs came in short of expectations, as the HSBC/Markit PMI slipped to a final 49.4 in June from the flash reading of 49.6, while the government's official manufacturing PMI fell to 50.1 in June from 50.9 in May. COMPANY NEWS: Shares of BP (BP) advanced after the oil major announced it has reached agreements in principle to settle all U.S. federal and state claims arising from the Deepwater Horizon accident and spill in 2010. BP said it will pay up to $18.7B to settle the claims and that the expected impact of its agreements would be to increase the cumulative pre-tax charge associated with the accident and spill by around $10B from $43.8B at the end of the first quarter... In a blockbuster deal in the insurance industry, ACE Limited (ACE) agreed to acquire Chubb (CB) in a cash and stock transaction valued at over $28B. The combination will create the number one global Property and Casualty insurance company by P&C underwriting income and the number two U.S. public P&C insurer by market cap. Elsewhere on the M&A front, managed healthcare company Centene (CNC) announced a definitive agreement to acquire managed health care services rival Health Net (HNT) in a cash and stock deal valued at approximately $6.8B, including the assumption of approximately $500M of debt. Additionally, Willis Group (WSH) agreed to combine in an all-stock merger of equals with Towers Watson (TW) and Chambers Street Properties (CSG) announced a merger agreement with Gramercy Property Trust (GPT)... U.S. airline stocks dropped after the Associated Press reported that the Justice Department is investigating potential "unlawful coordination" between companies attempting to artificially limit growth to keep fares high... Juno Therapeutics (JUNO) advanced after the company announced a ten-year global collaboration for the development and commercialization of immunotherapies with Celgene (CELG). As part of the deal, Celgene will make an initial payment of approximately $1B, which includes the purchase of approximately 9.1M shares of Juno stock at $93 per share... Pentair (PNR) gained after Nelson Peltz's Trian Group confirmed it has taken a 7.24% stake. Trian urged the company to consider acquisitions and other industrial parts makers, including SPX Corp. (SPW), Flowserve (FLS), Xylem (XYL) and Colfax (CFX), also advanced following the activist's disclosure of its position... In a ruling with implications for coal miners and electric utilities, the Supreme Court overturned the EPA's Mercury Admissions and Toxic Standard, or MATS, rule, stating that the regulator did not properly take into account the costs to utilities and others in the sector in implementing a national standard for the reduction of power plant emissions of mercury and other air toxins... General Motors (GM) reported its U.S. sales fell 3% in June compared to the same month of last year, while Ford (F) said its sales grew 1.6% last month compared to last year. FCA US, the parent of the Chrysler and Jeep brands, reported U.S. sales increased 8% compared with sales in June 2014... Bond insurers MBIA (MBI) and Assured Guaranty (AGO) declined amid the worries about the debt situation in Puerto Rico. INDEXES: The Dow fell about 1.25% to close at 17,730.11, the Nasdaq declined about 1.43% to close at 5,009.21, and the S&P 500 dropped about 1.22% to close at 2,076.78.
16:37 EDTPFEPfizer announces FDA acceptance for review of NDA for Xeljanz
Subscribe for More Information
10:00 EDTAZNOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: AT&T (T) upgraded to Outperform from Market Perform at Cowen... Acadia Realty Trust (AKR) upgraded to Buy from Neutral at Citi... Alliance Resource Partners (ARLP) upgraded to Buy from Hold at Deutsche Bank... ArcBest (ARCB) upgraded to Peer Perform from Underperform at Wolfe Research... AstraZeneca (AZN) upgraded to Buy from Hold at Berenberg... ConAgra (CAG) upgraded to Overweight from Equal Weight at Morgan Stanley... DuPont Fabros (DFT) upgraded to Buy from Neutral at Citi... EastGroup Properties (EGP) upgraded to Buy from Neutral at Citi... Galaxy Entertainment (GXYEY) upgraded to Hold from Sell at Deutsche Bank... GrubHub (GRUB) upgraded to Outperform from Sector Perform at RBC Capital... HealthSouth (HLS) upgraded to Outperform from Market Perform at JMP Securities... IGM Financial (IGIFF) upgraded to Sector Performer from Underperformer at CIBC... Kennametal (KMT) upgraded to Neutral from Underperform at BofA/Merrill... Kimco Realty (KIM) upgraded to Buy from Neutral at Citi... Kosmos (KOS) upgraded to Outperform at BMO Capital... MGM China (MCHVF) upgraded to Hold from Sell at Deutsche Bank... Regal Entertainment (RGC) upgraded to Neutral from Sell at B. Riley... SL Green Realty (SLG) upgraded to Buy from Neutral at Citi... SQM (SQM) upgraded to Buy from Hold at HSBC... Sands China (SCHYY) upgraded to Hold from Sell at Deutsche Bank... Terex (TEX) upgraded to Neutral from Underperform at BofA/Merrill... United Community Banks (UCBI) upgraded to Outperform from Market Perform at Raymond James... Weingarten Realty (WRI) upgraded to Buy from Neutral at Citi... Willis Group (WSH) upgraded to Neutral from Sell at Goldman... Wynn Macau (WYNMF) upgraded to Hold from Sell at Deutsche Bank.
09:31 EDTPFEXRpro Sciences acquires assets related to ion channel platform from Pfizer
XRpro Sciences announced its acquisition of assets related to the ion channel biology platform from Pfizer that had previously been obtained as part of Pfizer's 2011 acquisition of Icagen. XRPro Sciences also acquired all of Pfizer's rights to the "Icagen" name and trademark. XRPro Sciences is re-launching the Icagen brand and will provide comprehensive services for ion channel and transporter drug discovery, combining Icagen's industry-leading scientific expertise and extensive portfolio of assays and cell lines with XRpro Sciences' proprietary, label-free X-ray fluorescence technology. The new Icagen will continue to operate out of the existing facility in Research Triangle Park, North Carolina in addition to the current XRpro Sciences Inc. site in Cambridge, Massachusetts. Pfizer scientists associated with the ion channel biology platform will transition to the new Icagen, ensuring continuity of their extensive scientific expertise.
05:30 EDTAZNAstraZeneca upgraded to Buy from Hold at Berenberg
Subscribe for More Information
July 1, 2015
16:10 EDTCELGDoctor failed to disclose Celgene payment to medical journal, Bloomberg reports
Subscribe for More Information
16:00 EDTPFEOptions Update; July 1, 2015
Subscribe for More Information
08:30 EDTTEVATeva launches generic Aggrenox capsules in the U.S.
Teva announced the launch of generic Aggrenox capsules in the United States. Aspirin and extended-release dipyridamole capsules are used to lower the risk of stroke in people who have had a mini-stroke or stroke due to a blood clot. Aggrenox capsules had annual sales of approximately $457M in the United States, according to IMS data as of April.
08:11 EDTTEVATeva, Xenon provide update on TV-45070 Phase 2b study in OA pain
Subscribe for More Information
08:04 EDTTEVATeva, Xenon Pharmaceuticals provide update on TV-45070 Phase 2b study
Subscribe for More Information
08:01 EDTTEVATeva CEO: Pharma industry undergoing “very big shakeup,” Globes reports
Subscribe for More Information
June 30, 2015
12:57 EDTCELGOn The Fly: Top stock stories at midday
Stocks on Wall Street were mixed at midday as headlines about Greece once again dominate the news flow. Hopes that Greece may still reach a last-minute deal with its creditors were attributed for the market's early bounce, though optimism and the averages have been dropping as the day continues. ECONOMIC EVENTS: In the U.S., Case-Shiller 20-city composite home price index for April rose by a seasonally adjusted 0.3% month over month, versus the consensus forecast for an increase of 0.8%. The Chicago PMI jumped 3.2 points to 49.4 in June, though that was below the expected reading of 50.0. The Conference Board's consumer confidence index rose to 101.4 in June from a revised 94.6 reading for May, beating expectations for a reading of 97.4. In Europe, Greece's government submitted a proposal for a deal with the eurozone bailout fund to cover its debt repayments due between 2015 and 2017. Jeroen Dijsselbloem said eurozone finance ministers will discuss the Greek request in a conference call tonight, but German Chancellor Angela Merkel reportedly said that no new negotiations should take place before Greek holds its scheduled referendum. COMPANY NEWS: Shares of Pentair (PNR) advanced 5.5% after activist investor Nelson Peltz's Trian Group confirmed it has taken a 7.24% stake in the company. Trian noted it has met with the company’s senior management and communicated its view that the company can create significant value for its shareholders by facilitating "prudent industry consolidation" through accretive mergers and acquisitions as well as by making other changes, such as communicating its results as "cash" EPS... Another company in the sights of an activist, ConAgra (CAG), rose 1.5% after reporting first quarter results that were roughly in-line with expectations while also announcing that plans to exit Private Brands operations. ConAgra CEO Sean Connolly said during the associated call that he wants "constructive conversation" with Jana Partners, which reported earlier this month that it has taken a 7.2% stake in the packaged foods company and is prepared to seek three ConAgra board seats, if necessary, to help the board evaluate and address opportunities for shareholder value creation. MAJOR MOVERS: Among the notable gainers was Juno Therapeutics (JUNO), which jumped 19% after the company announced a ten-year global collaboration for the development and commercialization of immunotherapies with Celgene (CELG). As part of the deal, Celgene will make an initial payment of approximately $1B, which includes the purchase of approximately 9.1M shares of Juno stock at $93 per share. Also higher was TreeHouse Foods (THS), which gained 9% after peer ConAgra announced plans to exit its private brands operations. Among the noteworthy losers was Apollo Education (APOL), which dropped 16.5% and was downgraded at Bank of America Merrill Lynch after the for-profit education company reported higher than expected Q3 earnings but lowered its fiscal 2015 guidance. Also lower were shares of Tuesday Morning (TUES), which fell 13% after announcing that its CFO Jeffrey Boyer has resigned his position to take the same role with Pier 1 Imports (PIR). INDEXES: Near midday, the Dow was down 3.77, or 0.02%, to 17,592.58, the Nasdaq was up 11.24, or 0.23%, to 4,969.71, and the S&P 500 was flat near 2,057.81.
10:19 EDTAZNAstraZeneca, Eolas Therapeutics partner on EORA program for smoking cessation
Eolas Therapeutics said that is has entered into a worldwide license and partnership agreement with AstraZeneca on the Eolas Orexin-1 Receptor Antagonist program for smoking cessation and other indications. The EORA program was awarded a Blueprint Neurotherapeutics grant from the National Institutes of Health for the development of the program from the preclinical stage through phase I clinical trials. The total deal potential is in excess of $145M. This includes upfront, clinical and regulatory milestone payments. Additionally, Eolas is eligible to receive royalties on commercial sales.
09:05 EDTCELGCelgene may eventually acquire Juno, says Canaccord
Canaccord noted the deal between Celgene (CELG) and Juno Therapeutics (JUNO) and said the current deal structure may mean 2020 earnings may have to be adjusted lower as some of the company's programs are not eligible for a 50/50 split. Canaccord said Celgene may simply buy the rest of Juno to gain 100% of all the programs worldwide and reiterated its Buy rating and $156 price target on Celgene shares.
08:59 EDTCELGLion Biotech has positive read through from Celgene deal, says Roth Capital
Subscribe for More Information
08:53 EDTCELGJuno Therapeutics price target raised to $83 from $66 at JPMorgan
JPMorgan raised Overweight rated Juno Therapeutics' (JUNO) price target to $83 from $66 following the announcement of a 10 year collaboration with Celgene (CELG). The firm said the partnership between the companies will be stronger than either single company or two separate entities.
08:27 EDTTEVAPerrigo deal for Roxane would make Mylan fight harder, says Citi
Subscribe for More Information
08:08 EDTCELGCelgene deal positive, says JMP Securities
Subscribe for More Information
07:47 EDTCELGCelgene paid high price for CAR T access, says Bernstein
Subscribe for More Information
07:32 EDTCELGJuno pact leaves Celgene set for growth past Revlimid, says Deutsche Bank
Subscribe for More Information
07:14 EDTCELGCelgene deal with Juno Therapeutics probably good, says UBS
Subscribe for More Information
07:11 EDTCELGCelgene deal solidifies position in oncology, says Cantor
Subscribe for More Information
07:03 EDTCELGCelgene leaps forward in immuno-oncology with Juno deal, says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer said that Celgene (CELG) effectively spent $1B to buy into adoptive T cell therapy and own all of Juno Therapeutics' (JUNO) opportunities outside the U.S., leaping the company into a leading position in the immuno-oncology space. Schimmer additionally thinks Celgene's transaction should help boost investor confidence about the utility and value of CAR and TCR therapies, noting that he sees Bellicum Pharmaceuticals (BLCM), Cellectis (CLLS), Lion Biotechnologies (LBIO), bluebird bio (BLUE) and the Amgen (AMGN)-Kite Pharma (KITE) partnership as best positioned to compete in this rapidly advancing field. The analyst keeps an Overweight rating and $144 price target on Celgene.
07:03 EDTCELGJuno volatility low into announcing immunotherapy collaboration with Celgene
Subscribe for More Information
June 29, 2015
19:01 EDTCELGOn The Fly: After Hours Movers
HIGHER: Juno Therapeutics (JUNO), up 38.4% after announcing immunotherapy collaboration with Celgene (CELG)... Kite Pharma (KITE) and Lion Biotechnologies (LBIO) are up 8.7% and 5.7% respectively, following Juno's collaboration with Celgene. DOWN AFTER EARNINGS: CHC Group (HELI), down 8%... Apollo Education (APOL), down 6.2%. ALSO LOWER: EnteroMedics (ETRM), down 12.4% after filing to sell common stock and warrants... Celgene (CELG), down 1% after Juno announces immunotherapy collaboration.
18:09 EDTCELGJuno surges after Celgene collaboration, CAR-T peers follow
Subscribe for More Information
16:13 EDTAZNFibroGen announces receipt of $120M license payment from AstraZeneca
Subscribe for More Information
16:09 EDTCELGCelgene, Juno Therapeutics announce ten year collaboration
Celgene (CELG) and Juno Therapeutics (JUNO) announced a global collaboration for the development and commercialization of immunotherapies. The two companies will leverage T cell therapeutic strategies to develop treatments for patients with cancer and autoimmune diseases with an initial focus on Chimeric Antigen Receptor Technology and T Cell Receptor technologies. Under the terms of the collaboration, Celgene has the option to be the commercialization partner for Juno’s oncology and cell therapy auto-immune product candidates, including Juno’s CD19 and CD22 directed CAR-T product candidates. B-Cell Maturation Antigen is excluded as a target in this collaboration. Under the terms of the collaboration, Celgene has the option to be the commercialization partner for Juno’s oncology and cell therapy auto-immune product candidates, including Juno’s CD19 and CD22 directed CAR-T product candidates. B-Cell Maturation Antigen is excluded as a target in this collaboration. For Juno-originated programs co-developed under the collaboration: Juno will be responsible for research and development in North America and will retain commercialization rights in those territories; Celgene will be responsible for development and commercialization in the rest of the world, and will pay Juno a royalty on sales in those territories; and Celgene has certain co-promotion options: Celgene will initially be eligible to select two programs, excluding CD19 and CD22, to be subject to a global profit sharing agreement under which the companies will share worldwide expenses and profits equally, except in China; and Additionally, subject to additional obligations, Celgene may select a third program. Juno will have the option to enter into a co-development and co-commercialization agreement on certain Celgene-originated development candidates that target T Cells. For any such Celgene-originated programs co-developed under the collaboration: The parties will share global costs and profits with 70% allocated to Celgene and 30% allocated to Juno; and Celgene will lead global development and commercialization, subject to a Juno co-promote option in the US and certain EU territories. Upon closing, Juno will receive an upfront payment of approximately $150M, and in addition Celgene will purchase 9,137,672 shares of Juno’s common stock at $93.00 per share. In conjunction with this stock purchase: Celgene will receive the right to nominate a member to Juno’s board of directors; During the 10-year term of the collaboration, Celgene will have the right to purchase additional equity in Juno during specified windows and at specified market premiums subject to satisfaction of certain conditions by each party including Juno opting in on select Celgene programs, such that, at a maximum, Celgene could own up to 30% of Juno’s common stock then outstanding; and Celgene has entered into a standstill agreement and agreed to certain lock-up provisions on its share ownership. This transaction has been approved by the boards of directors of both companies. Celgene and Juno currently expect to complete the transaction during the third quarter of 2015, subject to the expiration or termination of applicable waiting periods under all applicable antitrust laws and satisfaction of other usual and customary closing conditions.
16:08 EDTCELGJuno jumps 45% after announcing immunotherapy collaboration with Celgene
Subscribe for More Information
16:07 EDTCELGCelgene, Juno Therapeutics announce ten year collaboration
Subscribe for More Information
June 26, 2015
11:32 EDTCELGCelgene looks to protect itself from Kyle Bass patent challenges, WSJ says
Subscribe for More Information
10:38 EDTTEVACourt revives lawsuit over GlaxoSmithKline Lamictal drug, Bloomberg reports
Subscribe for More Information
07:52 EDTALKSAlkermes schizophrenia drug profile looks interesting, says Cowen
Subscribe for More Information
June 25, 2015
14:00 EDTAZNAstraZeneca initiated with a Hold at HSBC
Price target GBP 46.40.
13:59 EDTTEVATeva initiated with a Hold at HSBC
Subscribe for More Information
12:52 EDTTEVAEU to decide by July 29 on Mylan's bid for Perrigo, Reuters reports
Subscribe for More Information
08:05 EDTTEVATeva, Active Biotech say patient enrollment finalized for CONCERTO trial
Subscribe for More Information
07:49 EDTPRXLPAREXEL shares should be bought on weakness, says Wells Fargo
Subscribe for More Information
June 24, 2015
13:23 EDTPFEPfizer says CDC committee votes to recommend MenB vaccine
Pfizer announced that the U.S. Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices voted to recommend that decisions to vaccinate adolescents and young adults 16 through 23 years of age against serogroup B meningococcal disease should be made at the individual level with healthcare providers. It added, "Specifically, the ACIP voted that a serogroup B meningococcal vaccine series may be administered to adolescents and young adults 16 through 23 years of age to provide short term protection against most strains of serogroup B meningococcal disease. The preferred age for MenB vaccination is 16 through 18 years of age." Pfizer's Trumenba is FDA-approved for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B in individuals 10 through 25 years of age. The ACIP recommendation will be forwarded to the director of the CDC and the U.S. Department of Health and Human Services for review and approval, Pfizer said.
11:02 EDTPFEPfizer lung cancer treatment granted FDA orphan drug designation
Subscribe for More Information
09:07 EDTPFE, AZNCAR-T cancer drug researchers seen as M&A targets, Bloomberg says
Juno Therapeutics (JUNO), Kite Pharma (KITE) and Bluebird Bio (BLUE) are trading well above their IPO levels as takeovers predictions have spurred interest and share increases for the developers of CAR-T gene therapies, said Bloomberg's "Real M&A" column, quoting Dimo Dimov, a professor at the University of Bath’s School of Management, as having said that companies such as Pfizer (PFE), Merck (MRK), Roche (RHHBY) and AstraZeneca (AZN) are "closely watching" the firms. Cellectis (CLLS), which is working with Pfizer on its own approach to CAR-T therapy, has said it wants to bring its therapy to market and doesn’t anticipate a sale, the report noted. Reference Link
08:04 EDTTEVATeva launches PainMatters.com to support ‘responsible pain management’
Subscribe for More Information
07:48 EDTALKSAlkermes data support ALKS 3831 potential, says Credit Suisse
Subscribe for More Information
07:26 EDTPRXLPAREXEL price target raised to $82 from $72 at UBS
UBS raised its price target on PAREXEL to $82 from $72 following the company's updated guidance. The firm sees gains from cost cutting, margin expansion and the growth of strategic partners. UBS reiterated its Buy rating on PAREXEL shares.
07:09 EDTACORAcorda says oral levodopa reduces duration of OFF episodes in PD patients
Subscribe for More Information
06:50 EDTAZNAstraZeneca loses top executive Ward-Lilley to Vectura, Reuters reports
Subscribe for More Information
05:51 EDTALKSAlkermes physician call on ALKS 3831 encouraging, says UBS
Subscribe for More Information
June 23, 2015
16:18 EDTPRXLPAREXEL maintains mid-point of prior FY15 EPS guidance at $2.74
Subscribe for More Information
16:17 EDTPRXLPAREXEL to record $35M-$45M charge from restructuring
Subscribe for More Information
16:13 EDTPRXLPAREXEL sees double digit growth in EPS for 2016
Subscribe for More Information
16:11 EDTPRXLPAREXEL sees FY16 EPS $3.02-$3.38, consensus $3.24
Sees FY16 revenue $2.16B-$2.21B, consensus $2.2B.
16:10 EDTPRXLPAREXEL narrows FY15 EPS view to $2.70-$2.78 from $2.65-$2.83, consensus $2.75
Subscribe for More Information
16:06 EDTPRXLPAREXEL sees Q4 EPS 70c-78c, consensus 75c
Subscribe for More Information
14:17 EDTPFEGlycoMimetics to receive $20M payment from Pfizer
Subscribe for More Information
14:16 EDTTEVABMO Capital sees strong fundamentals in Perrigo regardless of Mylan deal
Shares of Perrigo (PRGO) are trading higher intraday after BMO Capital Markets initiated coverage of the stock with an Outperform rating. The research firm is bullish on the shares regardless of whether Mylan's bid for the company succeeds, saying Perrigo is well-positioned to ride momentum in reduced-price healthcare. WHAT'S NEW: BMO Capital Markets' David Maris initiated coverage of Perrigo with an Outperform rating and a $246 price target. Maris cited the company's 70%-plus market share in store- and private-label brands, as well as its roughly $1B annual sales in the generics space. The analyst believes Perrigo will see continued benefit from larger trends driving consumer-centric healthcare and the curtailing of medical costs. WHAT'S NOTABLE: BMO Capital Markets noted that two upcoming Tysabri-related events are not accounted for by the Street, giving rise to a "significant" undervaluing of the shares. Mylan (MYL) has submitted multiple unsolicited offers for Perrigo, and while the likelihood of the deal seems low given Perrigo's numerous rejections and Teva's (TEVA) 4.61% blocking stake in Mylan. BMO Capital remarked that a failed deal should see "limited downside" for Perrigo. There could certainly be near-term volatility if a Mylan agreement doesn't materialize, but the analyst was confident in the well-positioned company's ability to deliver on both earnings per share and cash flow. PRICE ACTION: Shares of Perrigo are up nearly 2% in afternoon trading. The company saw a nearly 25% leap following Mylan's initial offer on April 8, though it has since dipped from that high.
14:01 EDTPFEPfizer announces enrollment of first patient in RESET study
Subscribe for More Information
09:53 EDTPFEPfizer management to meet with FBN Securities
Meeting to be held in New York on June 25 hosted by FBN Securities.
08:49 EDTTEVAMylan CFO to meet with Tel Aviv bourse head Wednesday, Reuters says
Subscribe for More Information
07:31 EDTAZNBIND Therapeutics announces FDA authorization of clinical trial with AZD2811
Subscribe for More Information
07:25 EDTPFEPiper Jaffray to hold a summit
2015 Piper Jaffray Heartland Summit is being held in Minneapolis on June 23-24.
June 22, 2015
08:52 EDTPFEPortola, Bristol-Myers, and Pfizer announce results from Phase 3 ANNEXA study
Subscribe for More Information
07:01 EDTPFEPfizer to acquire Nimenrix, Mencevax from GlaxoSmithKline for $130M
Pfizer (PFE) announced that it has entered into an agreement with GlaxoSmithKline (GSK) to acquire its quadrivalent meningitis ACWY vaccines, Nimenrix and Mencevax, for a total consideration of approximately $130M. This transaction will add two high-quality and complementary vaccines to Pfizer’s portfolio, allowing the company to reach a broader global population. Nimenrix is a single dose meningococcal ACWY-TT conjugated vaccine designed to protect against Neisseria meningitidis, an uncommon but highly contagious disease that can lead to disability and death. Mencevax is a single-dose meningococcal ACWY unconjugated polysaccharide vaccine used to control outbreaks of meningococcal infection and for travelers to countries where the disease is endemic or highly epidemic. Pfizer does not expect this transaction to have any significant impact on its 2015 financial performance. The transaction is subject to customary closing conditions as well as regulatory approvals in several markets, and is expected to occur in the second half of 2015. Pfizer’s legal advisors for the transaction were Ropes & Gray and Clifford Chance.
June 21, 2015
19:53 EDTTEVAMylan CEO says Teva's 4.61% stake may be 'illegal,' Bloomberg reports
Subscribe for More Information
June 19, 2015
15:53 EDTPRXLPAREXEL to host investor day
Subscribe for More Information
10:31 EDTALKSAlkermes to host conference call
Conference call to discuss the six-month data of ALKS 3831 for the treatment of schizophrenia will be held on June 23 at 8 am. Webcast Link
08:30 EDTTEVATeva completes purchase of 4.61% interest in Mylan
Subscribe for More Information
07:23 EDTTEVATeva data quite strong, says Bernstein
After Teva (TEVA) announced data for its TEV-48125 drug in episodic migraine, Bernstein notes that the drug met its primary and secondary endpoints. The firm says that the reduction in migraine days of Teva's drug appears to be higher than what Amgen (AMGN) and Lilly (LLY) have shown. The firm continues to see the migraine treatments from Teva and Alder as better than those from Lilly and Amgen.
<< 1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use